PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Rilvegostomig

Drugs in development · updated 30 October 2026

Rilvegostomig: clinical trials and development status

Other names and codes: AZD2936

FDA substance registryNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 Rilvegostomig is in 37 active clinical trials (recruiting or ongoing, phases I–III) for 33 diseases. The most advanced phase is III.

37Active trials
IIIMost advanced phase
33Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Rilvegostomig and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 33 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Non-small-cell lung carcinomaIII12NCT06692738
Stomach neoplasmIII8NCT07431281
Biliary tract neoplasmIII6NCT06109779
AdenocarcinomaIII3NCT07431281
Endometrial neoplasmIII3NCT06989112
CarcinomaIII2NCT07720284
CholangiocarcinomaIII2NCT06109779
Esophageal neoplasmIII2NCT07431281
Esophagus adenocarcinomaIII2NCT07431281
Gallbladder neoplasmIII2NCT06109779
Hepatocellular carcinomaIII2NCT06921785
Bile duct neoplasmIII1NCT06109779
Bladder neoplasmIII1NCT07720284
Klatskin's tumorIII1NCT06109779
Transitional cell carcinomaIII1NCT07720284
Uterine neoplasmIII1NCT06989112
Breast neoplasmII2NCT01042379
Head and neck squamous cell carcinomaI–II2NCT07115043
MelanomaI–II2NCT07115043
NeoplasmII2NCT01042379
Ovarian neoplasmII2NCT05489211
Renal cell carcinomaII2NCT03741426
Triple-negative breast neoplasmII2NCT01042379
Colorectal neoplasmII1NCT05489211
HemangiosarcomaII1NCT01042379
Lung neoplasmII1NCT05061550
Merkel cell carcinomaI–II1NCT07115043
MetastasisI–II1NCT04995523
Squamous cell carcinomaI–II1NCT07115043
Autosomal dominant Parkinson disease 4I1NCT07161414

Everything on Rilvegostomig

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch